Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108061 | 1.00 | LOXL2 (0.64) | LOXL2KDM4EALDH1A1MAPTHRH4 | |
| Iodide SCHEMBL28699913 | 0.98 | LOXL2 (0.62) | LOXL2KDM4EALDH1A1MAPTHRH4 | |
| Acetic Acid SCHEMBL30839816 | 0.89 | MTNR1A (0.59) | LOXL2KDM4EALDH1A1MAPTHRH4 | |
| Acetic Acid SCHEMBL11542186 | 0.89 | MTNR1A (0.59) | LOXL2KDM4EALDH1A1MAPTHRH4 | |
| Phosphoric Acid SCHEMBL30909011 | 0.89 | KDM4E (0.56) | LOXL2KDM4EALDH1A1MAPTHRH4 | |
| 2-Phenyl-1H-Indole SCHEMBL11095769 | 0.86 | NPC1 (0.71) | LOXL2KDM4EALDH1A1MAPT | |
| Quinoline SCHEMBL28270225 | 0.83 | ALDH1A1 (0.52) | LOXL2KDM4EALDH1A1MAPTHRH4 | |
| Butyric Acid SCHEMBL28501621 | 0.83 | KDM4E (0.50) | LOXL2KDM4EALDH1A1MAPTMTNR1A | |
| SCHEMBL30610463 | 0.83 | LOXL2 (0.60) | LOXL2KDM4EALDH1A1MAPTHRH4 | |
| SCHEMBL73259 | 0.83 | LOXL2 (0.60) | LOXL2KDM4EALDH1A1MAPTHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224179-A1 | GLUTAMINYL CYCLASE INHBITORS FOR USE IN THE TREATMENT OF KIDNEY DISEASE | VIVORYON THERAPEUTICS N.V. (DE) | 2025-10-30 | — | — | WO | disclosed |
| CN-118619875-B | Diindolyl group methane preparation method | 浙江师范大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-119080627-A | Synthesis method of roxburgh Bei Kao shake | 江苏慧聚药业股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118619875-A | Diindolyl group methane preparation method | 浙江师范大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-114890947-B | Aromatic heterocyclic compound containing quinoline structural unit, and preparation method and application thereof | 郑州大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-117794560-A | Stapled peptides and methods thereof | 弗格制药有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240093270-A1 | GENERATION AND SELECTION OF AFFINITY REAGENTS | NAUTILUS SUBSIDIARY, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2024036284-A1 | GENERATION AND SELECTION OF AFFINITY REAGENTS | NAUTILUS SUBSIDIARY, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| CN-114014264-A | Hydrogen storage material and preparation method thereof | 株洲铂陆新能源科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-114014264-A | Hydrogen storage material and preparation method thereof | 株洲铂陆新能源科技有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931412-B2 | JAK1 inhibitors and uses thereof | JAK1, JAK3, JAK2 | LOXL2 1397/4885KDM4E 2005/4885ALDH1A1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.